Belfer Institute and Evotec establish collaboration in oncology
The Belfer Institute for Applied cancer Science at Dana-Farber Cancer Institute and Evotec AG (EVT) announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms.
The goal of the collaboration is to validate emerging epigenetic targets for oncology indications and to demonstrate the drugability of the selected target families. Evotec, Dana-Farber and Dana-Farber's Belfer Institute for Applied Cancer Science will invest in enabling technologies, experimental target validation and the generation of chemical matter by leveraging existing expertise and platforms. The collaboration will be fuelled by substantial scientific contributions from the three organisations aligned on the objective to develop therapies that address unmet medical needs for cancer patients.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
John_Ensign

Successful laboratory test of photoswitchable anti-tumor agent
LifeSciences British Columbia - Vancouver, Canada

New tool for studying membrane protein structure
Wilson's_disease
List_of_eye_diseases_and_disorders
Clathrin
Deinagkistrodon
ThromboGenics Begins Phase III Program with Microplasmin for the Non-surgical Treatment of Back of the Eye Disease - ThromboGenics’ lead product to be studied in the treatment of vitreomacular adhesion in the US and Europe
